Skip to main content
    G

    GeoVax Labs Inc (GOVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.26
    +0.02 (+6.84%)

    Market Cap: $2.44M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(25/32)
    Avg Surprise
    +54.18%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.09
    Range$-1.09 - $-1.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.12+48.6%
    60d ago$-2.12+48.6%
    30d ago$-1.090.0%
    7d ago$-1.090.0%
    Current$-1.09
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.05
    Range$-1.05 - $-1.05
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.05---
    Sep 26EST
    		-$-1.09---
    Jun 26
    Reported Jul 27
    		$-0.97N/A+55.09%Beat+88.9%
    Mar 26
    Reported Apr 2
    		$-2.62$-0.84-211.90%Miss+76.7%
    Dec 25
    Reported Dec 31
    		$N/A$-5.35N/ABeat-
    Sep 25
    Reported Nov 13
    		$-7.75$-6.62-17.07%Miss+65.9%
    Jun 25
    Reported Jul 28
    		$-8.75$-9.00+2.78%Beat+82.4%
    Mar 25
    Reported May 1
    		$-11.25$-16.44+31.57%Beat-355.5%
    Dec 24
    Reported Mar 27
    		$-0.30N/A+60.94%Beat+99.7%
    Sep 24
    Reported Nov 12
    		$-22.75$-32.90+30.85%Beat+81.0%
    Jun 24
    Reported Aug 6
    		$-49.75$-84.12+40.86%Beat+39.7%
    Mar 24
    Reported May 14
    		$-2.47N/A+55.58%Beat+95.6%
    Dec 23
    Reported Feb 29
    		$-98.50$-105.00+6.19%Beat-49150.0%
    Sep 23
    Reported Nov 8
    		$-120.00$-90.00-33.33%Miss-88.2%
    Jun 23
    Reported Aug 9
    		$-82.50$-63.75-29.41%Miss-22.2%
    Mar 23
    Reported May 4
    		$-56.25$-84.37+33.33%Beat+55.9%
    Dec 22
    Reported Mar 23
    		$-0.20$-0.20+0.00%Beat+91.0%
    Sep 22
    Reported Nov 9
    		$-63.75$-45.00-41.67%Miss+45.2%
    Jun 22
    Reported Aug 3
    		$-67.50$-112.50+40.00%Beat+14.3%
    Mar 22
    Reported Apr 27
    		$-127.50$-116.25-9.68%Miss-43865.5%
    Dec 21
    Reported Mar 9
    		$-2.23$-0.40-457.50%Miss-100.8%
    Sep 21
    Reported Nov 11
    		$-116.25$-138.75+16.22%Beat-15824.7%
    Jun 21
    Reported Aug 11
    		$-78.75N/A+51.16%Beat-262400.0%
    Mar 21
    Reported May 6
    		$-0.29$-0.29+0.00%Beat-123.1%
    Dec 20
    Reported Mar 23
    		$266.25$-15.00+1875.00%Beat+10665.5%
    Sep 20
    Reported Nov 5
    		$-0.73$-0.73+0.00%Beat+100.0%
    Jun 20
    Reported Aug 10
    		$-0.03$-0.03+0.00%Beat+100.0%
    Mar 20
    Reported May 5
    		$-0.13$-0.13+0.00%Beat+100.0%
    Dec 19
    Reported Mar 24
    		$-2.52N/A+99.76%Beat+100.0%
    Sep 19
    Reported Nov 7
    		$-449999.77N/A+55.00%Beat-22592518.2%
    Jun 19
    Reported Aug 14
    		$-1000000.00$-1000000.00+0.00%Beat-48728094.1%
    Mar 19
    Reported May 13
    		$-57200.00N/AN/ABeat+71.4%
    Dec 18
    Reported Mar 27
    		$-1000000.00N/AN/ABeat-400.0%
    Sep 18
    Reported Nov 8
    		$-1.99N/AN/ABeat+100.0%
    Jun 18
    Reported Aug 7
    		$-2.05N/AN/ABeat+100.0%
    Mar 18
    Reported May 3
    		$-200000.00N/AN/ABeat-1999999900.0%
    Dec 17
    Reported Mar 23
    		$-200000.00N/A+80.00%Beat+80.0%
    Sep 17
    Reported Nov 9
    		$-1000000.00$-1000000.00+0.00%Beat-
    Jun 17
    Reported Aug 7
    		$-1000000.00$-1000000.00+0.00%Beat-
    Mar 17
    Reported May 8
    		$-0.01N/AN/ABeat-
    Dec 16
    Reported Mar 24
    		$-1000000.00$-1000000.00+0.00%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-892.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.54xQuick Ratio1.54x
    Trading Statistics
    Beta3.69Avg Volume875.90K
    52-Week High$15.2552-Week Low$0.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.28
    SMA 20$0.32
    SMA 50$0.49
    SMA 200$1.48
    EMA 10$0.28
    EMA 20$0.33
    EMA 50$0.50
    EMA 200$3.18

    MACD

    Line: -0.07Signal: -0.07Hist: 0.01

    ADX

    ADX: 18.0+DI: 19.5-DI: 27.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$0.39

    Bollinger Bands

    Upper Band$0.40
    Lower Band$0.24
    %B Position5124%(Upper)
    Band Width0.13

    RSI (14-Day)

    Oversold
    22.9

    Momentum Oscillators

    Stoch %K5.7
    Stoch %D4.6
    Williams %R-86.4
    ROC (10d)-20.0%
    Momentum-0.06
    CCI (20d)-137.2
    MFI (14d)74.5

    Volatility Measures

    ATR (14d)$0.04(16.3%)
    StdDev (20d)0.04
    Hist Vol66.6%(High)

    Volume Flow

    VWAP$0.25
    OBV206.3M
    AD Line110.4B
    CMF (20d)-0.706

    Volume Metrics

    Avg Vol (20d)934.2K
    Vol Ratio0.6x
    VWMA (20d)$0.31

    Pivot Points

    R3$0.30
    R2$0.29
    R1$0.27
    Pivot Point$0.25
    S1$0.23
    S2$0.22
    S3$0.19

    Advanced Oscillators

    TSI-57.92
    Ultimate Osc29.4
    KST-399.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$852,282$1.64M$864,415$2.79M$300,677$0$103,912$0
    Cost of Revenue$0$0N/A$0$0$0$21,641$0$0$0$22,213$0
    Gross Profit$0$0N/A$0$852,282$1.64M$864,415$2.79M$300,677$0$-22,213$0
    Operating Expenses$4.44M$5.27M$4.44M$6.37M$6.27M$7.04M$9.21M$8.64M$5.36M$5.88M$7.69M$8.60M
    R&D$3.11M$3.90M$2.99M$5.04M$4.73M$5.35M$7.61M$7.40M$4.28M$4.43M$6.23M$6.95M
    SG&A$1.33M$1.37M$1.45M$1.33M$1.54M$1.69M$1.60M$1.24M$1.09M$1.46M$1.46M$1.65M
    Operating Income$-4,442,072$-5,272,881$-4,441,756$-6,373,215$-5,418,906$-5,405,170$-8,344,402$-5,854,576$-5,062,221$-5,883,081$-7,693,750$-8,599,754
    Interest Income$15,494$10,960$23,333$54,301$49,123$47,519$81,748$53,191$5,471$32,949$101,342$190,936
    Interest Expense$0$0$0$0$0$0$0$14,083$7,292$0$0$0
    Income Before Tax$-4,426,578$-5,261,921$-4,418,423$-6,318,914$-5,369,783$-5,357,651$-8,262,654$-5,815,468$-5,064,042$-5,850,132$-7,592,408$-8,408,818
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,426,578$-5,261,921$-4,418,423$-6,318,914$-5,369,783$-5,357,651$-8,262,654$-5,815,468$-5,064,042$-5,850,132$-7,592,408$-8,408,818
    EBITDA$-4,429,996$-5,260,805$-4,423,526$-6,356,413$-5,402,103$-5,388,249$-8,322,761$-5,824,168$-5,038,478$-5,863,505$-7,671,537$-8,582,435
    EBIT$-4,442,072$-5,272,881$-4,441,756$-6,373,215$-5,418,906$-5,405,170$-8,344,402$-5,854,576$-5,062,221$-5,883,081$-7,693,750$-8,599,754
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GOVX

    News

    GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026

    GeoVax Labs, Inc. will present its next-generation MVA (Modified Vaccinia Ankara) vaccine technologies and manufacturing innovations at the World Vaccine Congress Europe 2026. Dr. Senthil Ranganathan will discuss...

    Yahoo Finance•10/6/26•Bullish

    GeoVax Labs, Inc. (GOVXW) Analyst insights, Price targets and Recommendations

    The article provides a snapshot of GeoVax Labs, Inc. (GOVXW) stock performance, showing a closing price of $0.0035 with a 23.91% decrease. It indicates that the information is from Yahoo Finance and includes a summary...

    Yahoo Finance Australia•10/3/26•Neutral

    GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

    GeoVax Labs, Inc. highlighted a significant shift in the U.S. mpox epidemiology, with the CDC reporting likely sustained domestic transmission of Clade Ib mpox. This development underscores the importance of continued...

    Yahoo Finance•9/29/26•Bullish

    GeoVax Labs, Inc. SEC Filing (Sep 24, 2026)

    GeoVax Labs, Inc. (GOVX) submitted an EFFECT form SEC filing on September 24, 2026, which was accepted by the SEC on the same day. This filing indicates that the S-1 registration statement became effective on September...

    Stock Titan•9/25/26•Neutral

    GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

    GeoVax Labs, Inc. announced preclinical research showing that a single administration of its enhanced MVA-X vaccine provides durable protection against orthopoxviruses...

    Yahoo Finance•9/22/26•Bullish

    GOVX Valuation and Fair Value

    Forward P/E
    9.7x
    PEG
    0.0x
    P/B
    0.7x
    See GNG's fair value

    GOVX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -892.0%

    GOVX Competitors

    CompanyTicker
    Matinas BioPharma Holdings IncMTNB
    Elevai Labs, Inc. Common StockELAB
    Kairos Pharma, Ltd.KAPA
    Flora Growth CorpFLGC
    Biomotion Sciences Ordinary SharesSLXN
    Virax Biolabs Group Limited Ordinary SharesVRAX
    iSpecimen IncISPC
    Scisparc LtdSPRC

    Sector: Healthcare

    GOVX Bull Case vs Bear Case

    Bull case

    • GOVX beat EPS estimates in 75.0% of its last 8 reported quarters.

    Bear case

    • GOVX's quarterly revenue changed -100.0% year over year.

    GOVX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    -0.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About GOVX

    Does GOVX pay dividends?

    GeoVax Labs Inc (GOVX) does not currently pay a regular dividend.

    What is GOVX's market cap?

    GeoVax Labs Inc (GOVX) has a market capitalization of $2.44M with a current stock price of $0.26.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In